Previous Helicobacter pylori infection–induced atrophic gastritis: A distinct disease entity in an understudied population without a history of eradication

Hiroshi Kishikawa, Keisuke Ojiro, Kenji Nakamura, Tadashi Katayama, Kyoko Arahata, Sakiko Takarabe, Soichiro Miura, Takanori Kanai, Jiro Nishida

Research output: Contribution to journalReview article

Abstract

Individuals with chronic atrophic gastritis who are negative for active H. pylori infection with no history of eradication therapy have been identified in clinical practice. By excluding false-negative and autoimmune gastritis cases, it can be surmised that most of these patients have experienced unintentional eradication of H. pylori after antibiotic treatment for other infectious disease, unreported successful eradication, or H. pylori that spontaneously disappeared. These patients are considered to have previous H. pylori infection–induced atrophic gastritis. In this work, we define these cases based on the following criteria: absence of previous H. pylori eradication; atrophic changes on endoscopy or histologic confirmation of glandular atrophy; negative for a current H. pylori infection diagnosed in the absence of proton-pump inhibitors or antibiotics; and absence of localized corpus atrophy, positivity for autoantibodies, or characteristic histologic findings suggestive of autoimmune gastritis. The risk of developing gastric cancer depends on the atrophic grade. The reported rate of developing gastric cancer is 0.31%-0.62% per year for successfully eradicated severely atrophic cases (pathophysiologically equal to unintentionally eradicated cases and unreported eradicated cases), and 0.53%-0.87% per year for spontaneously resolved cases due to severe atrophy. Therefore, for previous H. pylori infection–induced atrophic gastritis cases, we recommend endoscopic surveillance every 3 years for high-risk patients, including those with endoscopically severe atrophy or intestinal metaplasia. Because of the difficulty involved in the endoscopic diagnosis of gastric cancer in cases of previous infection, appropriate monitoring of the high-risk subgroup of this understudied population is especially important.

Original languageEnglish
Article numbere12669
JournalHelicobacter
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Atrophic Gastritis
Pylorus
Helicobacter pylori
Atrophy
Population
Stomach Neoplasms
Gastritis
Infection
Anti-Bacterial Agents
Proton Pump Inhibitors
Metaplasia
Autoantibodies
Endoscopy
Communicable Diseases
Therapeutics

Keywords

  • chronic atrophic gastritis
  • endoscopy
  • eradication
  • gastric autoimmune diseases
  • Helicobacter pylori diagnosis
  • Helicobacter pylori infection

ASJC Scopus subject areas

  • Gastroenterology
  • Infectious Diseases

Cite this

Previous Helicobacter pylori infection–induced atrophic gastritis : A distinct disease entity in an understudied population without a history of eradication. / Kishikawa, Hiroshi; Ojiro, Keisuke; Nakamura, Kenji; Katayama, Tadashi; Arahata, Kyoko; Takarabe, Sakiko; Miura, Soichiro; Kanai, Takanori; Nishida, Jiro.

In: Helicobacter, 01.01.2019.

Research output: Contribution to journalReview article

Kishikawa, Hiroshi ; Ojiro, Keisuke ; Nakamura, Kenji ; Katayama, Tadashi ; Arahata, Kyoko ; Takarabe, Sakiko ; Miura, Soichiro ; Kanai, Takanori ; Nishida, Jiro. / Previous Helicobacter pylori infection–induced atrophic gastritis : A distinct disease entity in an understudied population without a history of eradication. In: Helicobacter. 2019.
@article{755ad61dc84647d581a8c76cccb2b898,
title = "Previous Helicobacter pylori infection–induced atrophic gastritis: A distinct disease entity in an understudied population without a history of eradication",
abstract = "Individuals with chronic atrophic gastritis who are negative for active H. pylori infection with no history of eradication therapy have been identified in clinical practice. By excluding false-negative and autoimmune gastritis cases, it can be surmised that most of these patients have experienced unintentional eradication of H. pylori after antibiotic treatment for other infectious disease, unreported successful eradication, or H. pylori that spontaneously disappeared. These patients are considered to have previous H. pylori infection–induced atrophic gastritis. In this work, we define these cases based on the following criteria: absence of previous H. pylori eradication; atrophic changes on endoscopy or histologic confirmation of glandular atrophy; negative for a current H. pylori infection diagnosed in the absence of proton-pump inhibitors or antibiotics; and absence of localized corpus atrophy, positivity for autoantibodies, or characteristic histologic findings suggestive of autoimmune gastritis. The risk of developing gastric cancer depends on the atrophic grade. The reported rate of developing gastric cancer is 0.31{\%}-0.62{\%} per year for successfully eradicated severely atrophic cases (pathophysiologically equal to unintentionally eradicated cases and unreported eradicated cases), and 0.53{\%}-0.87{\%} per year for spontaneously resolved cases due to severe atrophy. Therefore, for previous H. pylori infection–induced atrophic gastritis cases, we recommend endoscopic surveillance every 3 years for high-risk patients, including those with endoscopically severe atrophy or intestinal metaplasia. Because of the difficulty involved in the endoscopic diagnosis of gastric cancer in cases of previous infection, appropriate monitoring of the high-risk subgroup of this understudied population is especially important.",
keywords = "chronic atrophic gastritis, endoscopy, eradication, gastric autoimmune diseases, Helicobacter pylori diagnosis, Helicobacter pylori infection",
author = "Hiroshi Kishikawa and Keisuke Ojiro and Kenji Nakamura and Tadashi Katayama and Kyoko Arahata and Sakiko Takarabe and Soichiro Miura and Takanori Kanai and Jiro Nishida",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/hel.12669",
language = "English",
journal = "Helicobacter",
issn = "1083-4389",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Previous Helicobacter pylori infection–induced atrophic gastritis

T2 - A distinct disease entity in an understudied population without a history of eradication

AU - Kishikawa, Hiroshi

AU - Ojiro, Keisuke

AU - Nakamura, Kenji

AU - Katayama, Tadashi

AU - Arahata, Kyoko

AU - Takarabe, Sakiko

AU - Miura, Soichiro

AU - Kanai, Takanori

AU - Nishida, Jiro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Individuals with chronic atrophic gastritis who are negative for active H. pylori infection with no history of eradication therapy have been identified in clinical practice. By excluding false-negative and autoimmune gastritis cases, it can be surmised that most of these patients have experienced unintentional eradication of H. pylori after antibiotic treatment for other infectious disease, unreported successful eradication, or H. pylori that spontaneously disappeared. These patients are considered to have previous H. pylori infection–induced atrophic gastritis. In this work, we define these cases based on the following criteria: absence of previous H. pylori eradication; atrophic changes on endoscopy or histologic confirmation of glandular atrophy; negative for a current H. pylori infection diagnosed in the absence of proton-pump inhibitors or antibiotics; and absence of localized corpus atrophy, positivity for autoantibodies, or characteristic histologic findings suggestive of autoimmune gastritis. The risk of developing gastric cancer depends on the atrophic grade. The reported rate of developing gastric cancer is 0.31%-0.62% per year for successfully eradicated severely atrophic cases (pathophysiologically equal to unintentionally eradicated cases and unreported eradicated cases), and 0.53%-0.87% per year for spontaneously resolved cases due to severe atrophy. Therefore, for previous H. pylori infection–induced atrophic gastritis cases, we recommend endoscopic surveillance every 3 years for high-risk patients, including those with endoscopically severe atrophy or intestinal metaplasia. Because of the difficulty involved in the endoscopic diagnosis of gastric cancer in cases of previous infection, appropriate monitoring of the high-risk subgroup of this understudied population is especially important.

AB - Individuals with chronic atrophic gastritis who are negative for active H. pylori infection with no history of eradication therapy have been identified in clinical practice. By excluding false-negative and autoimmune gastritis cases, it can be surmised that most of these patients have experienced unintentional eradication of H. pylori after antibiotic treatment for other infectious disease, unreported successful eradication, or H. pylori that spontaneously disappeared. These patients are considered to have previous H. pylori infection–induced atrophic gastritis. In this work, we define these cases based on the following criteria: absence of previous H. pylori eradication; atrophic changes on endoscopy or histologic confirmation of glandular atrophy; negative for a current H. pylori infection diagnosed in the absence of proton-pump inhibitors or antibiotics; and absence of localized corpus atrophy, positivity for autoantibodies, or characteristic histologic findings suggestive of autoimmune gastritis. The risk of developing gastric cancer depends on the atrophic grade. The reported rate of developing gastric cancer is 0.31%-0.62% per year for successfully eradicated severely atrophic cases (pathophysiologically equal to unintentionally eradicated cases and unreported eradicated cases), and 0.53%-0.87% per year for spontaneously resolved cases due to severe atrophy. Therefore, for previous H. pylori infection–induced atrophic gastritis cases, we recommend endoscopic surveillance every 3 years for high-risk patients, including those with endoscopically severe atrophy or intestinal metaplasia. Because of the difficulty involved in the endoscopic diagnosis of gastric cancer in cases of previous infection, appropriate monitoring of the high-risk subgroup of this understudied population is especially important.

KW - chronic atrophic gastritis

KW - endoscopy

KW - eradication

KW - gastric autoimmune diseases

KW - Helicobacter pylori diagnosis

KW - Helicobacter pylori infection

UR - http://www.scopus.com/inward/record.url?scp=85074749216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074749216&partnerID=8YFLogxK

U2 - 10.1111/hel.12669

DO - 10.1111/hel.12669

M3 - Review article

C2 - 31680399

AN - SCOPUS:85074749216

JO - Helicobacter

JF - Helicobacter

SN - 1083-4389

M1 - e12669

ER -